Title:
FUSION PROTEIN SLIT2D2(C386S)-HSA AND USE THEREOF IN TREATMENT OF FIBROTIC DISEASES
Document Type and Number:
WIPO Patent Application WO/2018/103631
Kind Code:
A1
Abstract:
The present invention provides a fusion protein of Slit2D2 (C386S) and HSA, and use thereof in the treatment and/or prevention of fibrotic diseases. In the fusion protein, cysteine at position 386 in Slit2D2 domain mutates into serine, which improves stability of the fusion protein. The fusion protein of Slit2D2 (C386S) and HSA prolongs drug metabolic time in vivo while improving the drug stability. The fusion protein of the present invention is effective in prevention and treatment of fibrotic diseases, especially pulmonary fibrosis.
Inventors:
LI HUASHUN (CN)
REN BAOYONG (CN)
LIU PENG (CN)
REN BAOYONG (CN)
LIU PENG (CN)
Application Number:
PCT/CN2017/114599
Publication Date:
June 14, 2018
Filing Date:
December 05, 2017
Export Citation:
Assignee:
LI HUASHUN (CN)
International Classes:
A61K38/17; C07K14/47; A61K47/64; A61P11/00; A61P31/00; C07K19/00; C12N15/12; C12N15/62
Domestic Patent References:
WO2015168469A1 | 2015-11-05 | |||
WO2016179861A1 | 2016-11-17 | |||
WO2014194402A1 | 2014-12-11 |
Foreign References:
CN106543278A | 2017-03-29 |
Other References:
LONDON , N. R.: "Targeting Robo4-Dependent Slit Signaling to Survive the Cytokine Storm in Sepsis and Influenza", SCIENCE TRANSLATIONAL MEDICINE, vol. 23, no. 2, 17 March 2010 (2010-03-17), pages 1 - 10, XP055375377
Attorney, Agent or Firm:
BEIJING BRIGHT IP AGENCY CO., LTD. (CN)
Download PDF: